Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil

Nakano, Takashi; Kuribayashi, Kozo; Mikami, Koji

doi:10.1080/14737140.2016.1241150

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…YS110 is a humanized mAb targeting CD26 that is currently under investigation in a phase I clinical trial (NCT03177668) in MPM patients. Preliminary results show that 50% (13/26) of patients achieved SD, with a median PFS of 43 days (128,129).…”

Section: Mesothelioma Targeting Antigensmentioning

confidence: 97%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

et al. 2020

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8-14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy and/or radiotherapy, in a small percentage of eligible patients and chemotherapy in tumors considered unresectable with or without adjuvant radiotherapy. In recent years, several new therapeutic avenues are being explored. These include angiogenesis inhibitors, synthetic lethal treatment, miRNA replacement, oncoviral therapies, and the fast-growing field of immunotherapy alone or in combination with chemotherapy. Of particular promise are the multiple options offered by immunotherapy: immune checkpoint inhibitors, tumor vaccines, and therapies taking advantage of tumor-specific antigens, such as specific therapeutic antibodies or advanced cell-based therapies exemplified by the CART cells. This review comprehensively presents both old and new therapeutic options in MPM, focusing on the results of the numerous recent and ongoing clinical trials in the field, including the latest data presented at international meetings (AACR, ASCO, and ESMO) this year, and concludes that more work has to be done in the framework of tailored therapies to identify reliable targets and novel biomarkers to impact MPM management.

show abstract

Section: Mesothelioma Targeting Antigensmentioning

confidence: 97%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Mesothelioma Targeting Antigensmentioning

confidence: 99%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Nicolini¹,

Bocchini²,

Bronte³

et al. 2021

Prime Archives in Cancer Research

View full text Add to dashboard Cite

Funding: Istituto Oncologico Romagnolo (IOR) and Becon AG through AFeVA, Associazione Familiari e Vittime Amianto, are funding our projects on malignant pleural mesothelioma. Neither of the funders contributed to the writing of this review. Conflict of Interest:The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments:We thank Alicja M. Gruszka, MD Ph.D., for her help in proofreading and editing this manuscript. We also thank Istituto Oncologico Romagnolo (IOR) and Becon AG through AFeVA, Associazione Familiari e Vittime Amianto for funding our projects on malignant pleural mesothelioma.

show abstract

“…While there was a transient decrease in total peripheral lymphocyte counts and CD26+ lymphocyte subsets following antibody administration, there was no observed autoimmune or infectious disease occurrences [ 99 ]. Furthermore, in this first-in-human phase I study, prolonged disease stabilization was observed in a significant number of patients that received YS110 [ 99 , 100 ]. Thirteen of 26 evaluable patients treated with YS110 had stable disease as the best response for an overall median PFS of 43 days, while 7 patients (including five cases of mesothelioma) experienced prolon-ged PFS of 184-399 days [ 99 , 100 ].…”

Section: Potential Approach To Targeting Cd26 In Mpmmentioning

confidence: 99%

“…Furthermore, in this first-in-human phase I study, prolonged disease stabilization was observed in a significant number of patients that received YS110 [ 99 , 100 ]. Thirteen of 26 evaluable patients treated with YS110 had stable disease as the best response for an overall median PFS of 43 days, while 7 patients (including five cases of mesothelioma) experienced prolon-ged PFS of 184-399 days [ 99 , 100 ]. Taken together, data from both preclinical studies as well as the recently completed first-in-human phase I clinical trial indicate that additional testing of YS110, which may represent a major breakthrough in the treatment of MPM, in future clinical trials as either single agent therapy or as part of combination therapies with other anti-neoplastic agents, would be warranted.…”

Section: Potential Approach To Targeting Cd26 In Mpmmentioning

confidence: 99%

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target

Doonan

Ohnuma

Dang

et al. 2017

CCTR

View full text Add to dashboard Cite

Background: Malignant mesothelioma is a largely incurable disease that is refractory to current therapies. CD26 is a multifunctional cell surface protein involved in autoimmune disease, diabetes, and cancer. It has a role in T cell function, extracellu-lar protein modification, as a prognostic factor for cancer, and as a therapeutic target for malignant mesothelioma. New treatment strategies are urgently needed for malig-nant pleural mesothelioma (MPM), and CD26-targeted therapy represents a novel ap-proach.Outline: In this review, the most current and up-to-date literature available was reviewed and the current state of malignant mesothelioma treatment is described. Throughout the review the need for new therapeutic approaches is highlighted in the shortcomings of current therapy. CD26 is a target that is fit to take on these shortcom-ings. In this review we discuss the structure and function of CD26, its role in malignant mesothelioma and the future of anti-CD26 therapy as a versatile immunotherapeutic option.Conclusion: This review highlights the areas of most promise in treating MPM, these in-clude immune checkpoint blockade, passive immunization, and based on our recently published data, targeting of CD26 with its specific mAb. Finally we describe how the an-ti-CD26 mAb YS110 was recently evaluated in the first-in-human phase I clinical trial, showing prolonged disease stabilization and a favorable side effect profile. Through better understanding of CD26, new pathways to treating and potentially curing malig-nant mesothelioma may be discovered.

show abstract

Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil

Cited by 4 publications

References 24 publications

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target

Contact Info

Product

Resources

About